Callisto Announces Additional Clinical Trial Sites for Atiprimod

Callisto Pharmaceuticals has opened two additional sites for the Phase I/IIa clinical trial of Atiprimod.

The new sites include the Roswell Park Cancer Institute in Buffalo, N.Y., and the St. Vincent's Comprehensive Cancer Center in New York.

Atiprimod is Callisto's lead drug candidate for treatment of multiple myeloma. The trial is presently underway at two leading cancer centers in the U.S., the Dana-Farber Cancer Institute in Boston and The University of Texas M. D. Anderson Cancer Center in Houston.